

> Return address Postbus 16114 2500 BC Den Haag

Office of Medicinal Cannabis

P.O. Box Postbus 16114 2500 BC Den Haag www.cannabisbureau.nl

Information info@cannabisbureau.nl T +31 70 340 5113

The Office of Medicinal Cannabis is part of the CIBG agency of the Ministry of Health, Welfare and Sport.

Subject Change Bedrolite[®] CBD specification

Dear sir, madam,

We would like to inform you about a change in the product specification of our **Cannabis Flos variety Bedrolite**[®] (granulate). The main ingredient of Bedrolite[®] is cannabidiol (CBD). **Since November 2021, the CBD specification has been changed from ca. 9%** $\pm 20\%$ **to ca. 7,5%** $\pm 20\%$.

Bedrolite[®] (granulate) is available for patient use since 2014. Over the years, our grower Bedrocan Nederland B.V. has acquired extensive expertise in growing this product. It has been found that the CBD-content of the Bedrolite variety, under standard cultivating conditions, is lower than the initially determined ca. 9%; namely 7.5% on average. The CBD specification of Bedrolite[®] is adjusted to this insight. This means the release specification for CBD in Bedrolite[®] is 6,0 - 9,0%, while this used to be 7,2 - 10,8%. The genetic composition and cultivation method remain the same.

The product retains its characteristic profile of active substances and the ratio CBD / THC (<1%) remains the same. Administration of the product can be continued in the same manner. Where previously the CBD content of all batches was \geq 7,2%, it is currently possible some batches have a CBD content between 6,0 and 7,2%.

If you or a patient need any further information, please do not hesitate to contact the Office of Medicinal Cannabis: info@cannabisbureau.nl

In case you would like to adjust your order in response to this notification, please let us know within one week.

Yours sincerely, The Office of Medicinal Cannabis